Eisai and TorreyPines Therapeutics Research Treatment for Alzheimer's Disease

22-Mar-2005

TorreyPines Therapeutics, Inc. and Eisai Co., Ltd. announced the signing of a research agreement involving Alzheimer's disease drug discovery.

The goal of the research performed by TorreyPines Therapeutics is to discover novel Alzheimer's disease modifying agents based on the study of the mechanism of the disease's pathogenesis. Under this agreement, Eisai will have exclusive rights of first negotiation and refusal for validated compounds discovered through the research. Eisai and TorreyPines Therapeutics may enter into drug development agreements involving certain validated compounds that meet a pre-determined set of criteria defined in the current agreement.

"We are pleased to work with Eisai once again in the field of Alzheimer's disease therapeutics," said Neil Kurtz, MD, President and CEO of Torrey Pines Therapeutics. "We look forward to advancing this program with Eisai's support, as well as continuing to work with them on our first research collaboration to identify genetically-validated pharmaceutical targets for Alzheimer's disease"

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances